IL178165A0 - Use of ppr delta agonists for treating demyelinating diseases - Google Patents
Use of ppr delta agonists for treating demyelinating diseasesInfo
- Publication number
- IL178165A0 IL178165A0 IL178165A IL17816506A IL178165A0 IL 178165 A0 IL178165 A0 IL 178165A0 IL 178165 A IL178165 A IL 178165A IL 17816506 A IL17816506 A IL 17816506A IL 178165 A0 IL178165 A0 IL 178165A0
- Authority
- IL
- Israel
- Prior art keywords
- ppr
- demyelinating diseases
- delta agonists
- treating demyelinating
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55853304P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/010371 WO2005097098A2 (en) | 2004-04-01 | 2005-03-29 | Use of ppr delta agonists for treating demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL178165A0 true IL178165A0 (en) | 2008-03-20 |
Family
ID=34977094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL178165A IL178165A0 (en) | 2004-04-01 | 2006-09-18 | Use of ppr delta agonists for treating demyelinating diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070149580A1 (https=) |
| EP (1) | EP1737440A2 (https=) |
| JP (1) | JP2007530703A (https=) |
| KR (1) | KR20060134191A (https=) |
| CN (1) | CN1950077A (https=) |
| AU (1) | AU2005231358A1 (https=) |
| BR (1) | BRPI0509540A (https=) |
| CA (1) | CA2561159A1 (https=) |
| IL (1) | IL178165A0 (https=) |
| MA (1) | MA28561B1 (https=) |
| MX (1) | MXPA06011218A (https=) |
| NO (1) | NO20064985L (https=) |
| RU (1) | RU2006138495A (https=) |
| SG (1) | SG138623A1 (https=) |
| WO (1) | WO2005097098A2 (https=) |
| ZA (1) | ZA200607850B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005024384D1 (de) | 2004-05-05 | 2010-12-09 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
| US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| EP1964575B1 (en) * | 2005-11-28 | 2015-09-23 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical comprising ppar agonist |
| CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
| US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
| US8716317B2 (en) | 2008-06-09 | 2014-05-06 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US8329725B2 (en) | 2008-06-09 | 2012-12-11 | Sanofi | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| KR20120107113A (ko) | 2009-12-17 | 2012-09-28 | 사노피 | 수초 염기성 단백질 프로모터(ｍｂｐ-ｌｕｃｉ)의 조절 하에 루시페라제를 발현하는 동물 모델 및 생물발광 생체내 영상화를 위한 상기 동물 모델의 용도 |
| JP6133790B2 (ja) * | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1856997A (en) * | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
| JPWO2004093910A1 (ja) * | 2003-04-22 | 2006-07-13 | アステラス製薬株式会社 | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
-
2005
- 2005-03-29 WO PCT/US2005/010371 patent/WO2005097098A2/en not_active Ceased
- 2005-03-29 RU RU2006138495/14A patent/RU2006138495A/ru not_active Application Discontinuation
- 2005-03-29 SG SG200800123-2A patent/SG138623A1/en unknown
- 2005-03-29 KR KR1020067022955A patent/KR20060134191A/ko not_active Withdrawn
- 2005-03-29 CA CA002561159A patent/CA2561159A1/en not_active Abandoned
- 2005-03-29 JP JP2007506442A patent/JP2007530703A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509540-9A patent/BRPI0509540A/pt not_active IP Right Cessation
- 2005-03-29 EP EP05729215A patent/EP1737440A2/en not_active Withdrawn
- 2005-03-29 MX MXPA06011218A patent/MXPA06011218A/es not_active Application Discontinuation
- 2005-03-29 CN CNA2005800148506A patent/CN1950077A/zh active Pending
- 2005-03-29 AU AU2005231358A patent/AU2005231358A1/en not_active Abandoned
-
2006
- 2006-09-18 IL IL178165A patent/IL178165A0/en unknown
- 2006-09-19 ZA ZA200607850A patent/ZA200607850B/xx unknown
- 2006-09-26 US US11/535,240 patent/US20070149580A1/en not_active Abandoned
- 2006-10-31 MA MA29427A patent/MA28561B1/fr unknown
- 2006-10-31 NO NO20064985A patent/NO20064985L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097098A2 (en) | 2005-10-20 |
| BRPI0509540A (pt) | 2007-09-18 |
| MXPA06011218A (es) | 2007-01-16 |
| CN1950077A (zh) | 2007-04-18 |
| KR20060134191A (ko) | 2006-12-27 |
| JP2007530703A (ja) | 2007-11-01 |
| ZA200607850B (en) | 2008-10-29 |
| EP1737440A2 (en) | 2007-01-03 |
| CA2561159A1 (en) | 2005-10-20 |
| NO20064985L (no) | 2006-10-31 |
| WO2005097098A3 (en) | 2005-12-22 |
| RU2006138495A (ru) | 2008-05-10 |
| US20070149580A1 (en) | 2007-06-28 |
| MA28561B1 (fr) | 2007-04-03 |
| SG138623A1 (en) | 2008-01-28 |
| AU2005231358A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| IL197933A0 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| PL2001892T3 (pl) | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| ZA200801253B (en) | Novel use of peptide compounds for treating muscle pain | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| IL176028A0 (en) | Compounds for treatment of cell proliferative diseases | |
| EP1737482A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| EP2019649A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING BODILUM DISORDER DISORDERS | |
| IL183506A0 (en) | Compositions and methods for treating neoplastic diseases | |
| IL173386A0 (en) | Use of adcc-optimized antibodies for treating weak patients | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| IL178165A0 (en) | Use of ppr delta agonists for treating demyelinating diseases | |
| EP1701735A4 (en) | METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF DIABETES | |
| EP1709155A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE | |
| IL179210A0 (en) | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | |
| EP1867640A4 (en) | MEANS FOR TREATING SOLID TUMORS | |
| IL188894A0 (en) | Compounds for treatment of lipase-mediated diseases | |
| IL175775A0 (en) | Process for the preparation of tubulin inhibitors | |
| PT1742937E (pt) | Derivados de pirrolopirimidina úteis para o tratamento de doenças proliferativas | |
| ZA200704971B (en) | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| IL189077A0 (en) | Novel use of peptide compounds for treating muscle pain | |
| IL178990A0 (en) | Methods of treating demyelinating disorders |